Your browser doesn't support javascript.
loading
Spatially resolved niche and tumor microenvironmental alterations in gastric cancer peritoneal metastases.
Zhao, Joseph J; Johnny Ong, Chin-Ann; Srivatsava, Supriya; Ann Chia, Daryl Kai; Ma, Haoran; Huang, Kiekyon; Sheng, Taotao; Ramnarayanan, Kalpana; Ong, Xuewen; Tay, Su Ting; Hagihara, Takeshi; Keng Tan, Angie Lay; Ching Teo, Melissa Ching; Tan, Qiu Xuan; Ng, Gillian; Wee-Shan Tan, Joey; Hsien Ng, Matthew Chau; Gwee, Yong Xiang; Walsh, Robert; Law, Jia Hao; Shabbir, Asim; Kim, Guowei; Tay, Yvonne; Her, Zhisheng; Leoncini, Giuseppe; Teh, Bin Tean; Hong, Jing Han; Kiat Tay, Ryan Yong; Teo, Chong Boon; Dings, Mark P G; Bijlsma, Maarten; Yew Lum, Jeffrey Huey; Mathur, Sachin; Pietrantonio, Filippo; Blum, Steven M; van Laarhoven, Hanneke; Klempner, Samuel J; Yong, Wei Peng; Yan So, Jimmy Bok; Chen, Qingfeng; Tan, Patrick; Sundar, Raghav.
Afiliación
  • Zhao JJ; Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Haematology-Oncology, National University Cancer Institute, Singapore; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore; Department of Medicine, National University Hospital, Singapore
  • Johnny Ong CA; Department of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore; Department of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, Singapore General Hospital, Singapore; Laboratory
  • Srivatsava S; Department of Medicine, National University of Singapore, Singapore.
  • Ann Chia DK; Department of Surgery, University Surgical Cluster, National University Health System, Singapore.
  • Ma H; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
  • Huang K; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
  • Sheng T; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
  • Ramnarayanan K; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
  • Ong X; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
  • Tay ST; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
  • Hagihara T; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
  • Keng Tan AL; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
  • Ching Teo MC; Department of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore; Department of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, Singapore General Hospital, Singapore.
  • Tan QX; Department of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore; Department of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, Singapore General Hospital, Singapore; Laboratory
  • Ng G; Department of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore; Department of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, Singapore General Hospital, Singapore; Laboratory
  • Wee-Shan Tan J; Department of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore; Department of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, Singapore General Hospital, Singapore; Laboratory
  • Hsien Ng MC; Division of Medical Oncology, National Cancer Centre, Singapore.
  • Gwee YX; Department of Haematology-Oncology, National University Cancer Institute, Singapore.
  • Walsh R; Department of Haematology-Oncology, National University Cancer Institute, Singapore.
  • Law JH; Department of Surgery, University Surgical Cluster, National University Health System, Singapore.
  • Shabbir A; Department of Surgery, University Surgical Cluster, National University Health System, Singapore.
  • Kim G; Department of Surgery, University Surgical Cluster, National University Health System, Singapore.
  • Tay Y; Cancer Science Institute of Singapore, National University of Singapore, Singapore; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Her Z; Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore.
  • Leoncini G; Pathology and Laboratory Medicine Dept, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Teh BT; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
  • Hong JH; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
  • Kiat Tay RY; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Teo CB; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Dings MPG; Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and Radiobiology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands; Oncode Institute, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
  • Bijlsma M; Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and Radiobiology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands; Oncode Institute, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
  • Yew Lum JH; Department of Pathology, National University Hospital, Singapore.
  • Mathur S; Department of General Surgery, Division of Surgery and Surgical Oncology, Singapore General Hospital.
  • Pietrantonio F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Blum SM; Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, MA, USA.
  • van Laarhoven H; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands; Department of Medical Oncology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.
  • Klempner SJ; Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, MA, USA.
  • Yong WP; Department of Haematology-Oncology, National University Cancer Institute, Singapore; Singapore Gastric Cancer Consortium, Singapore, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
  • Yan So JB; Department of Haematology-Oncology, National University Cancer Institute, Singapore; Singapore Gastric Cancer Consortium, Singapore, Singapore; Department of Surgery, University Surgical Cluster, National University Health System, Singapore; Division of Surgical Oncology, National University Cancer
  • Chen Q; Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore. Electronic address: qchen@imcb.a-star.edu.sg.
  • Tan P; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore; Singapore Gastric Cancer Consortium, Singapore, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore; Genome Institute of Singapore, Agency for Science, Technology and Research, Singapo
  • Sundar R; Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Haematology-Oncology, National University Cancer Institute, Singapore; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore; Singapore Gastric Cancer Consortium, Singapore, Singapore; The
Gastroenterology ; 2024 Aug 13.
Article en En | MEDLINE | ID: mdl-39147169
ABSTRACT
BACKGROUND AND

AIMS:

Peritoneal metastasis (PM) in gastric cancer (GC) is associated with poor prognosis and significant morbidity. We sought to understand the genomic, transcriptomic, and tumor microenvironment (TME) features that contribute to peritoneal organotropism in GC.

METHODS:

We conducted a comprehensive multi-omic analysis of 548 samples from 326 patients, including primary tumors, matched normal tissues, peritoneal metastases, and adjacent-normal peritoneal tissues. We employed whole exome sequencing, whole transcriptome sequencing, and digital spatial profiling to investigate molecular alterations, gene expression patterns, and TME characteristics associated with PM.

RESULTS:

Our analysis identified specific genomic alterations in primary tumors, including mutations in ELF3, CDH1, and PIGR, and TME signatures, such as stromal infiltration and M2 macrophage enrichment, associated with increased risk of PM. We observed distinct transcriptional programs and immune compositions in GCPM compared to liver metastases, highlighting the importance of the TME in transcoelomic metastasis. We found differential expression of therapeutic targets between primary tumors and PM, with lower CLDN18.2 and FGFR2b expression in PM. We unravel the roles of the TME in niche reprogramming within the peritoneum, and provide evidence of pre-metastatic niche conditioning even in early GC without clinical PM. These findings were further validated using a humanized mouse model, which demonstrated niche remodeling in the peritoneum during transcoelomic metastasis.

CONCLUSION:

Our study provides a comprehensive molecular characterization of GCPM and unveils key biological principles underlying transcoelomic metastasis. The identified predictive markers, therapeutic targets, and TME alterations offer potential avenues for targeted interventions and improved patient outcomes.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Gastroenterology Año: 2024 Tipo del documento: Article País de afiliación: Singapur

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Gastroenterology Año: 2024 Tipo del documento: Article País de afiliación: Singapur